Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics (NASDAQ: KROS) has responded to ADAR1 Capital Management's recent communications regarding the upcoming 2025 Annual Meeting. The company's Board announced it is conducting a strategic review process through an independent committee to evaluate options including a potential sale, continued pipeline investment, or return of capital to shareholders. The review follows a significant $200 million upfront payment from a licensing deal with Takeda, which could yield up to $1.1 billion in additional milestones plus royalties.
ADAR1 has opposed the re-election of two independent directors unless their CIO is added to the Board, pushing for immediate capital return to shareholders. Keros's Board, comprising nine directors (eight independent), recommends shareholders vote "FOR" its three director nominees at the June 4, 2025 Annual Meeting. The company highlights its strong cash position, funding operations into 2029.
ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest stockholder with a 13.3% stake, has released an open letter expressing concerns about the company's performance and direction. The activist investor announced plans to withhold votes for directors Dr. Mary Ann Gray and Dr. Alpna Seth at the June 4, 2025 stockholder meeting.
ADAR1 criticizes Keros for concerning clinical results in two drug candidates (KER-012 and KER-065) and calls for major restructuring, including a 70% headcount reduction and return of excess capital to shareholders. The company holds over $720 million in cash as of March 31, 2025. ADAR1 believes their proposed changes could deliver $24-35 per share in value, focusing on KER-050's partnership with Takeda, which they estimate could achieve $2 billion in peak sales.
Keros Therapeutics (NASDAQ: KROS) has announced that its Board of Directors has initiated a formal strategic alternatives review process to maximize stockholder value. The review will be overseen by a newly formed Strategic Committee of independent directors who will evaluate options including:
- potential sale of the company
- business combination transactions
- continued pipeline investment
- return of excess capital to stockholders
Additionally, the Board has implemented a -duration stockholder rights plan ('poison pill') in response to significant stock accumulations, including an 11.2% stake by an individual investor as of April 6, 2025. The rights plan triggers if any entity acquires 10% ownership (15% for passive institutional investors) without Board approval. The plan expires on April 9, 2026. The company expects to provide a preliminary update on the strategic review within 60 days.
Keros Therapeutics (NASDAQ: KROS) has announced positive initial topline results from its Phase 1 clinical trial of KER-065 in healthy volunteers. The trial successfully met its key objectives for safety, tolerability, and pharmacological measures through the multiple ascending dose treatment period.
Key findings as of February 6, 2025, showed that KER-065 was generally well-tolerated with no serious adverse events or dose-limiting toxicities. The drug demonstrated evidence of activin inhibition through:
- Increases in bone formation biomarkers and decreases in bone resorption markers
- Positive changes in fat mobilization biomarkers
- Improvements in body composition, including increased bone mineral density and muscle mass
Based on these results, Keros plans to engage with regulatory authorities in Q3 2025 and aims to initiate a Phase 2 clinical trial for Duchenne muscular dystrophy (DMD) patients in Q1 2026.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in two major healthcare conferences.
The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:
- The TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 9:50 a.m. ET
- The Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET
Both presentations will be in a fireside chat format, with archived replays available on the Keros website's Investor section for 90 days post-event.
Keros Therapeutics (NASDAQ: KROS) reported its Q4 and full-year 2024 financial results, highlighting a net loss of $46.0M for Q4 and $187.4M for the full year. The company's revenue increased to $3.0M in Q4 and $3.6M for 2024, primarily due to a milestone achievement under the Hansoh license agreement.
Research and development expenses rose to $173.6M for 2024, up from $135.3M in 2023, reflecting increased pipeline development activities. The company's cash position was significantly strengthened by a $200M upfront payment from Takeda Pharmaceuticals through an exclusive license agreement for elritercept development.
With cash and cash equivalents of $559.9M as of December 31, 2024, plus the Takeda payment, Keros expects to fund operations into 2029. The company anticipates reporting initial Phase 1 data for KER-065 in healthy volunteers in Q1 2025 and data from the Phase 2 TROPOS trial evaluating cibotercept in pulmonary arterial hypertension patients.
Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on Thursday, February 6, 2025, at 10:00 a.m. Eastern time.
The presentation will be accessible through a live audio webcast at the provided link, and an archived version will remain available on the Keros website's Investor section for up to 90 days after the event. This presentation represents an opportunity for investors and interested parties to gain insights into the company's developments and strategies.
Keros Therapeutics (Nasdaq: KROS) announced the effectiveness of its global development and commercialization license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept, effective January 16, 2025. The agreement, initially announced on December 3, 2024, was finalized following the expiration of the Hart-Scott Rodino Antitrust Improvements Act waiting period. As part of the agreement, Takeda will make an upfront payment of $200.0 million to Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.
Keros Therapeutics (NASDAQ: KROS) has announced the complete halt of dosing in its Phase 2 TROPOS trial of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) due to new observations of pericardial effusion adverse events. This decision extends to all treatment arms, including the 1.5 mg/kg and placebo groups, following a previous halt of the 3.0 mg/kg and 4.5 mg/kg treatment arms announced on December 12, 2024.
The company has notified investigators and regulatory authorities, including the FDA, about the early termination of the trial. Patients will be monitored through end-of-trial visits. Despite the setback, Keros maintains its timeline to present topline data from all treatment arms in the second quarter of 2025.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
